UroGen Pharma Ltd. (URGN)

Market Cap	466.01M
Revenue (ttm)	90.40M
Net Income (ttm)	-126.87M
Shares Out	46.09M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	565,680
Open	10.11
Previous Close	10.20
Day's Range	9.97 - 10.11
52-Week Range	8.94 - 20.70
Beta	0.81
Analysts	Strong Buy
Price Target	37.21 (+268.05%)
Earnings Date	May 12, 2025

About URGN

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $37.21, which is an increase of 268.05% from the latest price.

Price Target

$37.21

(268.05% upside)

Analyst Consensus: Strong Buy